Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.
Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Cao S, et al. Among authors: wang w, wang jr. Nat Biotechnol. 2022 Nov;40(11):1624-1633. doi: 10.1038/s41587-022-01342-x. Epub 2022 Jun 13. Nat Biotechnol. 2022. PMID: 35697807 Free PMC article.
Recent developments in the management of germ cell tumors.
Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM. Msaouel P, et al. Curr Opin Oncol. 2017 May;29(3):172-178. doi: 10.1097/CCO.0000000000000361. Curr Opin Oncol. 2017. PMID: 28151756 Free PMC article.
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Tannir NM, et al. Eur Urol Oncol. 2020 Oct;3(5):687-694. doi: 10.1016/j.euo.2019.06.004. Epub 2019 Jul 2. Eur Urol Oncol. 2020. PMID: 31272939 Free PMC article. Clinical Trial.
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.
Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. Boukovala M, et al. Eur J Cancer. 2020 Mar;127:67-75. doi: 10.1016/j.ejca.2019.12.027. Epub 2020 Jan 24. Eur J Cancer. 2020. PMID: 31986451 Free PMC article. Clinical Trial.
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. Spetsieris N, et al. Clin Genitourin Cancer. 2021 Feb;19(1):22-31.e5. doi: 10.1016/j.clgc.2020.05.013. Epub 2020 May 30. Clin Genitourin Cancer. 2021. PMID: 32675015 Free PMC article. Clinical Trial.
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Siddiqui BA, et al. J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850. J Immunother Cancer. 2021. PMID: 34326169 Free PMC article.
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Spetsieris N, et al. Eur J Cancer. 2021 Nov;157:259-267. doi: 10.1016/j.ejca.2021.06.017. Epub 2021 Sep 15. Eur J Cancer. 2021. PMID: 34536949 Clinical Trial.
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.
Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Alhalabi O, et al. Eur Urol Oncol. 2023 Apr;6(2):228-232. doi: 10.1016/j.euo.2021.10.006. Epub 2021 Nov 14. Eur Urol Oncol. 2023. PMID: 34789422 Free PMC article.
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. Alhalabi O, et al. Nat Commun. 2022 Apr 4;13(1):1797. doi: 10.1038/s41467-022-29397-z. Nat Commun. 2022. PMID: 35379845 Free PMC article. Clinical Trial.
882 results